Related Experiment Video
Updated: Jul 13, 2025
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review
Mengmeng Zhang1, Yingbo Li1, Zilong Zhang2
1College of Humanities and Management, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, P.R. China.
Abstract:
The BET protein family plays a crucial role in regulating the epigenetic landscape of the genome. Their role in regulating tumor-related gene expression and its impact on the survival of tumor cells is widely acknowledged. Among the BET family constituents, BRD4 is a significant protein. It is a bromodomain-containing protein located at the outer terminal that recognizes histones that have undergone acetylation. It is present in the promoter or enhancer region of the target gene and is responsible for initiating and sustaining the expression of genes associated with tumorigenesis. BRD4 expression is significantly elevated in various tumor types. Research has indicated that BRD4 plays a significant role in regulating various transcription factors and chromatin modification, as well as in repairing DNA damage and preserving telomere function, ultimately contributing to the survival of cancerous cells. The protein BRD4 has a significant impact on antitumor therapy, particularly in the management of lung cancer and hematological malignancies, and the promising potential of BRD4 inhibitors in the realm of cancer prevention and treatment is a topic of great interest. Therefore, BRD4 is considered a promising candidate for prophylaxis and therapy of neoplastic diseases. However, further research is required to fully comprehend the significance and indispensability of BRD4 in cancer and its potential as a therapeutic target.
Insights
BRD4, a key BET protein, drives cancer cell survival by regulating gene expression and DNA repair. Inhibiting BRD4 shows promise for cancer prevention and treatment, especially in lung cancer.
Area of Science:
- Epigenetics and Molecular Biology
- Cancer Biology
- Genomics
Background:
- The Bromodomain and Extra-Terminal domain (BET) protein family regulates the genome's epigenetic landscape.
- BRD4, a significant BET protein, recognizes acetylated histones and drives tumorigenesis by initiating gene expression.
- Elevated BRD4 expression is observed across various cancer types, contributing to tumor cell survival.
Approach:
- This research reviews the multifaceted roles of BRD4 in cancer.
- It examines BRD4's involvement in transcription factor regulation, chromatin modification, DNA repair, and telomere maintenance.
- The study highlights BRD4's impact on antitumor therapies and its potential as a therapeutic target.
Key Points:
- BRD4 is crucial for the expression of genes associated with tumorigenesis.
- It plays a significant role in DNA damage repair and telomere maintenance, aiding cancer cell survival.
- BRD4 is a promising target for cancer prophylaxis and therapy, particularly in lung cancer and hematological malignancies.
Conclusions:
- BRD4 is a vital protein in cancer development and progression.
- BRD4 inhibitors represent a promising therapeutic strategy for various cancers.
- Further research is needed to fully elucidate BRD4's role and therapeutic potential in oncology.
